Broad-Spectrum Anti-Infective Peptides for Resistant Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics face challenges such as high resistance from bacteria, limited topical options, and the difficulty in developing new classes of antibiotics due to competition from generic drugs and lengthy development times, leading to ineffective treatments for infections like MRSA and viral infections like Zika virus, which lack effective countermeasures.
Innovation Solution
Development of anti-infective peptides with broad-spectrum activity against both bacteria and viruses, possessing a therapeutic index greater than 10, low cytotoxicity, and solubility in aqueous solutions, which can be administered topically or through various routes, including pegylation or lipidation to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If common antibiotics are used to treat bacterial infections, then bacterial infections can be treated, but bacterial resistance develops making the antibiotics ineffective
Solution Approach 1:
The patent changes the fundamental parameter of the antimicrobial agent from conventional small-molecule antibiotics to peptide-based compounds. This parameter change enables broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as viral infections, while maintaining effectiveness against multidrug-resistant strains including MRSA, VRE, and CRE through a novel mechanism of action that bypasses traditional resistance pathways
Solution Approach 2:
The patent employs composite peptide structures combining hydrophobic and hydrophilic regions, with specific amino acid compositions (including cationic residues like arginine and lysine) that enable the peptides to interact with and disrupt microbial membranes. This composite structure at the molecular level provides both antibacterial and antiviral activity while overcoming resistance to conventional antibiotics
2Adaptability or versatility
If new antibiotics are developed, then treatment options for resistant infections improve, but development time and cost increase significantly
Solution Approach 1:
The patent segments the complex process of new antibiotic development by utilizing peptide synthesis technology that allows for rapid generation and testing of multiple peptide variants. This segmentation enables researchers to systematically optimize peptide sequences for specific antimicrobial activities against different pathogen types, significantly reducing the traditional drug development timeline
Solution Approach 2:
The patent changes the chemical parameter space by exploring peptide-based compounds rather than traditional small-molecule antibiotics. This parameter change opens access to entirely new classes of antimicrobials with novel mechanisms of action, providing fresh treatment options for resistant infections without requiring decades of conventional drug development
3Reliability
If membrane-active peptides are used for antibacterial activity, then potent activity against resistant bacteria is achieved, but cytotoxicity against human cells increases
Solution Approach 1:
The patent applies local quality differentiation by designing peptides with specific amino acid distributions that create distinct interactions with microbial versus human cell membranes. The peptides exhibit preferential binding to bacterial membranes through localized cationic and hydrophobic regions, while the overall peptide structure and charge distribution minimize interaction with human cell membranes, thereby reducing cytotoxicity
Solution Approach 2:
The patent utilizes partial action by designing peptides that require specific concentrations and contact times to achieve antimicrobial effects. At therapeutic concentrations, the peptides selectively target and disrupt microbial membranes while human cells remain unaffected due to differences in membrane composition and peptide binding affinity, effectively separating the therapeutic action from harmful side effects
4Ease of operation
If topical antibiotics are used for skin infections, then localized treatment is provided, but the options are limited and resistance still develops
Solution Approach 1:
The patent achieves universality by developing peptide compounds that simultaneously provide antibacterial activity against both Gram-positive and Gram-negative bacteria, as well as antiviral activity. This multi-functional capability allows a single topical formulation to treat a broad range of skin infections including MRSA, VRE, CRE, and viral infections like herpes and HPV, greatly expanding treatment options beyond conventional single-target antibiotics
Data Source
AI summary
Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.